Santaris Pharma

Santaris Pharma

Biopharmaceutical company focused on the discovery and development of rna-targeted therapies. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
CAD614m (Public information from Aug 2014)
Company register number 20690003
Hørsholm Capital Region of Denmark (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022
Revenues--26.5m----
EBITDA4.5m8.5m4.0m6.6m23.4m2.3m5.1m
% EBITDA margin--15 %----
Profit8.8m5.1m<1m6.1m(20.8m)<1m1.2m
R&D budget5.2m5.6m5.8m4.1m5.8m7.9m10.5m
R&D % of revenue--22 %----

Source: Dealroom estimates

  • Edit

Recent News about Santaris Pharma

Edit
More about Santaris Pharmainfo icon
Edit

Santaris is a pioneering healthcare company dedicated to addressing the global crisis of antimicrobial resistance and advancing personalized cancer care. Operating in the biotechnology and pharmaceutical sectors, Santaris collaborates with healthcare systems, industry partners, NGOs, governments, and regulatory bodies worldwide. The company serves a diverse range of clients, including hospitals, research institutions, and healthcare providers, aiming to improve patient outcomes through innovative solutions and cutting-edge research.

Santaris's business model revolves around developing and commercializing novel therapeutics and diagnostic tools. By leveraging strategic partnerships and a robust R&D pipeline, the company generates revenue through product sales, licensing agreements, and collaborative research funding. Santaris's commitment to global collaboration and innovation positions it as a leader in the fight against infectious diseases and cancer.

Keywords: antimicrobial resistance, personalized healthcare, cancer care, biotechnology, pharmaceuticals, global collaboration, diagnostics, therapeutics, R&D, healthcare innovation.